To Evaluate Clinical Outcome and Injection Compliance of Scilin (SEAS)

Bayer

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Insulin (Scilin R _BAY81-9924; Drug: Insulin (Scilin N, BAY81-9924); Drug: Insulin(Scilin M30_BAY81-9924)

Study type: Observational

Funder types: Industry

Identifiers

NCT01588639

SL1210CN (Other Identifier)

16372

Details and patient eligibility

About

This is a prospective, multi-center, open-label, non-interventional, 12-week study in people with type 2 diabetes mellitus who are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice. The term study insulins will be used in this protocol for these drugs and combinations.

Enrollment: 2,683 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Based on physicians' clinical judgement, subjects who are treated with SciLin N, SciLin R and SciLin M30 ( alone or in combination) will be eligible to be included in this clinical study.

Exclusion criteria

Subjects with one of the conditions listed below will be excluded:

Women who are pregnant, breast feeding or have the intention of becoming pregnant within the next 6 months Subjects who have to be treated with other insulins simultaneously Subjects who are participating in other diabetes clinical studies at the same time

Trial design

2,683 participants in 1 patient group

Group 1

Treatment:

Drug: Insulin(Scilin M30_BAY81-9924)

Drug: Insulin (Scilin N, BAY81-9924)

Drug: Insulin (Scilin R _BAY81-9924